What are the side effects of Orforglipron?

Release date: 2026-09-22 10:52:37     Article From: Lucius Laos     Recommended: 33

The most common adverse reactions of Orforglipron are gastrointestinal effects—nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, abdominal distension, eructation, gastroesophageal reflux, and flatulence, as well as headache, fatigue, and alopecia. Most are mild to moderate in severity, most prominent during the dose titration period, and decrease over time.

Common Adverse Reactions

Nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux disease, flatulence, and alopecia.

General pattern of side effects: The incidence of nausea, vomiting, and diarrhea is higher during the dose escalation phase and decreases over time. Higher doses generally correspond to a higher frequency of adverse events, though the relationship is not strictly linear.

The incidence of nausea increases from 26% at 5.5 mg to 35% at 17.2 mg, whereas constipation peaks at 27% with 9 mg and slightly decreases to 24% at 17.2 mg. This indicates that while the severity of reactions is related to dosage, individual variation remains significant.

Adverse Reactions Associated with Laboratory and Clinical Parameter Changes

Acute kidney injury, hypoglycemia, decreased blood pressure, tachycardia, diabetic retinopathy, and elevated pancreatic amylase and lipase.

Patients must strictly follow physician instructions to undergo regular monitoring of renal function, blood glucose, blood pressure, heart rate, and fundoscopic eye examinations.

Side Effects Requiring Immediate Medical Attention

1. Persistent or severe upper abdominal pain that may radiate to the back, with or without nausea and vomiting—acute pancreatitis should be suspected. If pancreatitis is suspected, discontinue treatment and seek medical care.

2. Severe or persistent gastrointestinal symptoms, such as intractable vomiting, severe diarrhea, or inability to tolerate oral intake of food and fluids—these represent severe gastrointestinal adverse reactions and warrant contacting a doctor.

3. Persistent or prolonged nausea, vomiting, or diarrhea, or signs such as marked thirst, decreased urine output, fatigue, or dizziness—acute kidney injury secondary to dehydration should be suspected, and reported to your doctor promptly.

4. Symptoms of hypoglycemia include: dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or somnolence, shakiness, weakness, headache, fast heartbeat, or restlessness. Risk is significantly increased, especially in patients using insulin or sulfonylureas. If these manifestations occur, manage them according to your doctor's pre-established instructions and report to your healthcare provider.

5. Swelling of the face, lips, tongue, or throat; fainting or dizziness; difficulty breathing or swallowing; rapid heart rate; or severe rash and itching—severe allergic reactions, including anaphylaxis and angioedema, should be suspected. Discontinue the medication and seek emergency medical care immediately.

6. Upper right abdominal pain, yellowing of the skin or whites of the eyes (jaundice), fever, or clay-colored stools—gallbladder disease should be suspected, and you should contact your doctor for gallbladder-related evaluations and follow-up.

7. Vision changes in diabetic patients—worsening of diabetic retinopathy should be suspected and reported to your doctor. Transient worsening of diabetic retinopathy has been reported following rapid improvements in blood glucose.

8. Planned surgery or procedures requiring general anesthesia or deep sedation—due to the risk of pulmonary aspiration during anesthesia, all medical personnel must be informed in advance. Postmarketing reports of pulmonary aspiration during elective procedures have occurred with this class of medications.

9. A mass or swelling in the neck, persistent hoarseness, difficulty swallowing, or shortness of breath—thyroid tumors should be suspected, which fall under a boxed warning; report these symptoms to your physician immediately.

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

  • Whatsapp

    Name: Lucius

  • Telegram name: Vira

    No.:0085253923643

Lucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved Lucius Pharmaceuticals Lucius Laos 老挝全球药房

WhatsApp

Telegram name: Vira

No.:0085253923643